Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real-World Multicenter Study.

International journal of urology : official journal of the Japanese Urological Association·2026

Same author

Essential Renal Bleeding Presenting as Persistent Unilateral Hematuria Successfully Treated With Factor XIII Replacement Therapy: A Case Report.

IJU case reports·2026

Same author

Perioperative Outcomes of Robot-Assisted Partial Nephrectomy Using Hinotori Compared With da Vinci Xi: A Propensity Score-matched Analysis.

The international journal of medical robotics + computer assisted surgery : MRCAS·2026

Same author

Emphysematous Pyelonephritis Caused by Klebsiella pneumoniae Complicated With Multiple Metastatic Abscesses and Transient Respiratory Arrest: A Case Report.

Cureus·2026

Same author

Nationwide Real-World Outcomes of Robot-Assisted Radical Prostatectomy Using the Hinotori Surgical Robot System in Japan.

International journal of urology : official journal of the Japanese Urological Association·2026

Same author

Dermatopathological Findings of an Erythema Multiforme-Like Drug Eruption During Enfortumab Vedotin Plus Pembrolizumab Therapy for Metastatic Urothelial Carcinoma: A Case Report.

Clinical case reports·2026

Search research articles

Related Experiment Video

Updated: Feb 28, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Recent progress in immunotherapy for urological cancer.

Wataru Obara¹, Renpei Kato¹, Yoichiro Kato¹

¹Department of Urology, Iwate Medical University School of Medicine, Morioka, Japan.

International Journal of Urology : Official Journal of the Japanese Urological Association

|June 22, 2017

Summary

Recent advances in cancer immunotherapy, including immune checkpoint inhibitors and therapeutic vaccines, have transformed urological cancer treatment. Further biomarker development is crucial for optimizing patient benefits from these novel strategies.

Keywords:

biomarker cancer immunotherapy cancer vaccine immune checkpoint inhibitor urological cancer

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Experiment Videos

Last Updated: Feb 28, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Area of Science:

Urology
Oncology
Immunology

Background:

Cancer immunotherapy for urological tumors has evolved significantly over decades.
Recent breakthroughs in therapeutic vaccines and immune checkpoint inhibitors have reshaped treatment paradigms.

Purpose of the Study:

To review the current landscape of cancer immunotherapy for urological cancers.
To highlight recent FDA approvals and ongoing clinical trials.
To discuss the need for improved biomarkers and novel therapeutic combinations.

Main Methods:

Review of recent scientific literature and clinical trial data.
Analysis of approved immunotherapy agents and emerging treatments.
Discussion of biomarker strategies for treatment response prediction.

Main Results:

Nivolumab and atezolizumab are approved by the FDA for urological cancers.
Numerous immune checkpoint inhibitors and vaccines are in clinical trials.
Current immunotherapies benefit only a subset of patients, necessitating further research.

Conclusions:

Cancer immunotherapy has made substantial progress in treating urological tumors.
Novel agents, combinations, and biomarker development are essential for enhancing efficacy.
Personalized treatment approaches are key to maximizing patient outcomes in urological oncology.